Galderma Group AG (GDERF)
| Market Cap | 39.60B |
| Revenue (ttm) | 4.69B |
| Net Income (ttm) | 378.00M |
| Shares Out | n/a |
| EPS (ttm) | 1.59 |
| PE Ratio | 104.75 |
| Forward PE | 49.60 |
| Dividend | 0.18 (0.11%) |
| Ex-Dividend Date | Apr 25, 2025 |
| Volume | 900 |
| Average Volume | 1,031 |
| Open | 165.00 |
| Previous Close | 162.10 |
| Day's Range | 163.60 - 166.50 |
| 52-Week Range | 81.32 - 166.50 |
| Beta | n/a |
| RSI | 98.32 |
| Earnings Date | Jul 24, 2025 |
About Galderma Group AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Actinica, Dysport/Azzalure, Alluzience, Restylane and Restylane Skinboosters, Sculptra, Cetaphil and Alastin, Soolantra, Epiduo and Epiduo Forte, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Mirvaso, Nemluvio, Relfydess, Benzac, Loceryl, and TRI-LUMA in ... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
Galderma Announces Departure of Its Chief Financial Officer
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that Thomas Dittrich, Chief Financial Officer, will be leaving the company t...
Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of ...
Galderma establishes new U.S. headquarters in Miami and strengthens regional leadership
Strategic move aims to accelerate innovation and growth in the U.S., Galderma's largest region MIAMI , June 17, 2025 /PRNewswire/ -- Galderma (SIX: GALD), the pure-play dermatology category leader, to...